Cita APA (7a ed.)

Alamón, C., Dávila Saralegui, B., García Melián, M. F., Sánchez, C., Kovacs, M., Trias, E., . . . Cerecetto, H. (2020). Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity.

Cita Chicago Style (17a ed.)

Alamón, Catalina, et al. Sunitinib-containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful in Vivo Anti-glioblastoma Activity. 2020.

Cita MLA (9a ed.)

Alamón, Catalina, et al. Sunitinib-containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful in Vivo Anti-glioblastoma Activity. 2020.